GlassScriptPhysician profile
Moiz M Carim
NPI 1720083330
$6,232.18
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $344 · 2021: $966 · 2022: $1,202 · 2023: $1,346 · 2024: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $902.14 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $748.65 | 2019-2024 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $644.56 | 2019-2024 | Eylea Hd, Eylea |
| Abbvie INC. | $417.70 | 2022-2024 | Ozurdex, Vuity, Lumigan |
| Alcon Vision LLC | $409.60 | 2019-2024 | Clareon |
| Bausch & Lomb Americas INC. | $355.22 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $345.15 | 2019-2022 | |
| Coherus Oncology, INC. | $296.06 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $225.67 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $220.27 | 2022-2024 | Syfovre |
| Eyepoint US, INC. | $192.97 | 2019-2022 | |
| Horizon Therapeutics Plc | $183.31 | 2021-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $177.37 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $168.33 | 2019-2021 | |
| Astellas Pharma US INC | $163.32 | 2023-2024 | Izervay |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $150.00 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $106.91 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $104.62 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $90.18 | 2019-2021 | |
| Sandoz INC. | $87.59 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $60.23 | 2020-2021 | |
| Omeros Corporation | $40.21 | 2019 | |
| Tearlab Corp | $33.99 | 2021 | |
| Biotissue Holdings INC. | $33.92 | 2020-2021 | |
| Shire North American Group INC | $21.05 | 2019 | |
| Vyera Pharmaceuticals, LLC | $19.08 | 2019 | |
| Celularity INC. | $18.96 | 2021 | |
| Spark Therapeutics, INC. | $15.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moiz Carim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.